LLY.SW Eli Lilly (SIX) -11.11% on 09 Mar 2026: valuation re-rate may deepen

The LLY.SW stock closed at CHF800.00 on 09 Mar 2026, down -11.11% after a CHF100.00 intraday move as Swiss trading ended. This sharp fall pushed volume to 12.00 shares and left the stock below its 50-day average (CHF829.90). Investors in Eli Lilly and Company (LLY.SW) on the SIX market will weigh valuation concerns against strong earnings metrics and product momentum while markets are closed.

LLY.SW stock: Market close and price action

LLY.SW stock finished the SIX session at CHF800.00, a -11.11% drop from the previous close of CHF900.00. The one-day change was -CHF100.00 on tiny traded volume of 12.00 shares, reflecting a concentrated move into market close. The year high and low are CHF900.00 and CHF540.00 respectively, giving a wide range for traders to watch when markets reopen.

LLY.SW stock: Fundamentals and valuation

Eli Lilly and Company shows solid underlying profitability with EPS CHF17.70 and a trailing PE of 45.20, reflecting premium valuation versus peers. Market cap stands at CHF616,403,227,200.00 and the stock trades above its 200-day average (CHF707.40) but below its 50-day mean (CHF829.90). Key ratios: price-to-sales 12.17, price-to-book 34.81, dividend yield 0.61%, and free cash flow per share CHF9.53 provide a mixed signal of strong cash generation but elevated multiples.

LLY.SW stock: Meyka AI grade and model forecast

Meyka AI rates LLY.SW with a score of 76.80 out of 100 (Grade B+, Suggestion: BUY). This grade factors S&P 500 and sector comparison, financial growth, key metrics, analyst consensus and forecasts. Meyka AI’s forecast model projects a monthly price of CHF733.39 (implied -8.33% vs current), a quarterly price of CHF760.29 (implied -4.96%), and a yearly target of CHF974.73 (implied +21.84%). Forecasts are model-based projections and not guarantees.

LLY.SW stock: Technical signals and short-term outlook

Technicals show near-term weakness: RSI 37.84 and MACD histogram negative at -7.33, suggesting momentum to the downside while ADX at 19.59 shows no strong trend. Bollinger middle band sits at CHF819.25 and lower band at CHF746.98, giving an immediate support zone around CHF747.00. Traders should watch the CHF746.98 lower band and the 200-day average CHF707.40 for support if selling continues.

LLY.SW stock: Sector context and peer comparison

In the Healthcare sector on SIX, Eli Lilly trades at a premium: sector average PE is 33.86 versus LLY’s 45.20. Peer names include Roche (RO.SW) and Novartis (NOVN.SW) where valuation and volume profiles differ. Sector performance YTD is -2.25%; Lilly’s one-day fall amplifies that drag and could prompt rotation toward lower PE healthcare names.

LLY.SW stock: Risks and near-term catalysts

Key risks include regulatory outcomes, pricing pressure, and patent timelines. Inventory and working capital metrics show long operating cycles with days of inventory on hand 453.91, heightening supply-chain sensitivity. Watch the next earnings announcement on 2026-04-30 and any regulatory updates, which could drive further re-rating when markets reopen.

Final Thoughts

LLY.SW stock’s CHF800.00 close on 09 Mar 2026 reflects a meaningful re-rate that exposed valuation sensitivity in a low-volume move. Fundamentals remain intact: EPS CHF17.70, strong free cash flow per share CHF9.53, and robust margins, but elevated multiples (PE 45.20, P/B 34.81) increase downside risk during short-term shocks. Meyka AI’s model gives a mixed near-term view (monthly CHF733.39, quarterly CHF760.29) and a one-year projection of CHF974.73, an implied upside of +21.84% versus today’s price. Investors should balance the potential one-year upside against near-term technical weakness (RSI 37.84) and sector dynamics. As an AI-powered market analysis platform, Meyka AI flags the grade B+ (BUY) but stresses forecasts are model-based and not guarantees. Monitor trading volume, the upcoming 2026-04-30 earnings release, and peer moves before adjusting positions.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.